BeiGene Announces Positive Regulatory Updates in Europe and the U.S. After Recently Regaining Global Rights for TEVIMBRA® September 26, 2023
1ST Biotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate FB849 in Combination With KEYTRUDA September 26, 2023
Collaborative Trial to Study PP2A Inhibitor, LB-100, Plus Dostarlimab, in Clear-Cell Ovarian Cancer announced September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Taiho Oncology to Evaluate LYTGOBI + BBI-355 in Patients with FGFR Amplified Solid Tumors September 26, 2023
Boundless Bio Announces Clinical Trial Collaboration & Supply Agreement with Lilly to Evaluate VERZENIO + BBI-355 in Patients with CDK4/6 Amplified Solid Tumors September 26, 2023
Debiopharm and SunRock Biopharma Partner to Advance Antibody Drug Conjugates for Hard-to-treat Cancers September 26, 2023
Ph 2 Study of Masofaniten (EPI-7386) + Enzalutamide in Patients with Metastatic CRPC initiated September 26, 2023
First Patient Dosed in Ph 1/2a Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer September 26, 2023
First Patient dosed in Ph 1/2 Trial of IMPT-314 for the Treatment of Aggressive B-cell Lymphoma September 26, 2023
First Patient in Ph 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ September 26, 2023
FAILED TRIALS: Ph 3 trials, LEAP-006 and LEAP-008, of KEYTRUDA + LENVIMA in patients with certain types of mNSCLC did not meet primary endpoints of OS & PFS September 26, 2023
PADCEV and KEYTRUDA Significantly Improve OS and PFS in Patients With Previously Untreated Advanced Bladder Cancer in Ph 3 EV-302 Trial September 26, 2023
Yescarta Demonstrates High Response Rate And Durable Remission In ALYCANTE Study As Initial Treatment For Transplant-Ineligible Patients With R/R LBCL September 26, 2023
Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial September 26, 2023
Perioperative Regimen of Neoadjuvant Opdivo and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves EFS in Patients with Resectable NSCLC September 26, 2023
Ph 3 KEYNOTE-A39/EV-302 Trial Met Dual Primary Endpoints of OS and PFS in Certain Patients With 1L Locally Advanced or Metastatic Urothelial Cancer September 26, 2023
FDA Accepts for Priority Review Supplemental NDA for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced RCC September 26, 2023
U.S. FDA Fast Track Designation for KT-333 for the Treatment of R/R Cutaneous T-Cell Lymphoma and R/R Peripheral T-Cell Lymphoma September 26, 2023
FDA Grants Priority Review to KEYTRUDA + Concurrent ChemoRT as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer September 26, 2023
European Commission approved INAQOVI® (oral decitabine and cedazuridine) for 1L AML patients September 26, 2023
